1
项与 Anti-CD33/CLL1 CAR-NK(Hangzhou Yingbairui Biomedical ) 相关的临床试验Clinical Study of Conjugated Antibody Redirecting Natural Killer (CAR-NK) Cells Targeting CD33 and CLL1 in Patients With Acute Myeloid Leukemia
This is an open-label, nonrandomized, investigator-initiated clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of anti-CD33/CLL1 CAR-NK cell injection in patients with acute myeloid leukemia (AML), and to determine PK parameters, maximum tolerated dose (MTD), and phase II recommended dose (RP2D) for subjects receiving CAR-NK cell injection.
100 项与 Anti-CD33/CLL1 CAR-NK(Hangzhou Yingbairui Biomedical ) 相关的临床结果
100 项与 Anti-CD33/CLL1 CAR-NK(Hangzhou Yingbairui Biomedical ) 相关的转化医学
100 项与 Anti-CD33/CLL1 CAR-NK(Hangzhou Yingbairui Biomedical ) 相关的专利(医药)
100 项与 Anti-CD33/CLL1 CAR-NK(Hangzhou Yingbairui Biomedical ) 相关的药物交易